Synopsis
Synopsis
0
CEP/COS
0
KDMF
0
VMF
DRUG PRODUCT COMPOSITIONS
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
1. 901, Hoe
2. A21 Gly B31 Arg B32 Arg Insulin
3. A21-gly-b31-arg-b32-arg-insulin
4. Basaglar
5. Glargine
6. Glargine, Insulin
7. Glargine-aglr, Insulin
8. Hoe 901
9. Hoe-901
10. Hoe901
11. Insulin Glargine
12. Insulin Glargine-aglr
13. Insulin Glargine-yfgn
14. Insulin, Gly(a21)-arg(b31,b32)
15. Insulin, Glycyl(a21)-arginyl(b31,b32)
16. Lantus
17. Lantus Solostar
18. Rezvoglar
19. Semglee
20. Solostar, Lantus
1. Gtpl7572
2. Hoe901
3. Hoe-901
Molecular Weight | 6063 g/mol |
---|---|
Molecular Formula | C267H404N72O78S6 |
XLogP3 | -14.1 |
Hydrogen Bond Donor Count | 85 |
Hydrogen Bond Acceptor Count | 92 |
Rotatable Bond Count | 191 |
Exact Mass | 6060.8251182 g/mol |
Monoisotopic Mass | 6058.8184085 g/mol |
Topological Polar Surface Area | 2590 Ų |
Heavy Atom Count | 423 |
Formal Charge | 0 |
Complexity | 15300 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 53 |
Undefined Atom Stereocenter Count | 0 |
Defined Bond Stereocenter Count | 0 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 1 |
1 of 2 | |
---|---|
Drug Name | Lantus |
PubMed Health | Insulin Glargine |
Drug Classes | Antidiabetic, Insulin, Long Acting |
Drug Label | LANTUS (insulin glargine [rDNA origin] injection) is a sterile solution of insulin glargine for use as a subcutaneous injection. Insulin glargine is a recombinant human insulin analog that is a long-acting (up to 24-hour duration of action), parenter... |
Active Ingredient | Insulin glargine recombinant |
Dosage Form | Injectable |
Route | Injection |
Strength | 100 units/ml |
Market Status | Prescription |
Company | Sanofi Aventis Us |
2 of 2 | |
---|---|
Drug Name | Lantus |
PubMed Health | Insulin Glargine |
Drug Classes | Antidiabetic, Insulin, Long Acting |
Drug Label | LANTUS (insulin glargine [rDNA origin] injection) is a sterile solution of insulin glargine for use as a subcutaneous injection. Insulin glargine is a recombinant human insulin analog that is a long-acting (up to 24-hour duration of action), parenter... |
Active Ingredient | Insulin glargine recombinant |
Dosage Form | Injectable |
Route | Injection |
Strength | 100 units/ml |
Market Status | Prescription |
Company | Sanofi Aventis Us |
Hypoglycemic Agents
Substances which lower blood glucose levels. (See all compounds classified as Hypoglycemic Agents.)
API/FDF Prices: Book a Demo to explore the features and consider upgrading later
API Imports and Exports
Importing Country | Total Quantity (KGS) |
Average Price (USD/KGS) |
Number of Transactions |
---|
Upgrade, download data, analyse, strategize, subscribe with us
Related Excipient Companies
Excipients by Applications
Global Sales Information
Market Place
Patents & EXCLUSIVITIES
REF. STANDARDS & IMPURITIES
ABOUT THIS PAGE
14
PharmaCompass offers a list of Insulin Glargine API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Insulin Glargine manufacturer or Insulin Glargine supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Insulin Glargine manufacturer or Insulin Glargine supplier.
PharmaCompass also assists you with knowing the Insulin Glargine API Price utilized in the formulation of products. Insulin Glargine API Price is not always fixed or binding as the Insulin Glargine Price is obtained through a variety of data sources. The Insulin Glargine Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.
A INSULIN GLARGINE (RDNA ORIGIN) manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of INSULIN GLARGINE (RDNA ORIGIN), including repackagers and relabelers. The FDA regulates INSULIN GLARGINE (RDNA ORIGIN) manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. INSULIN GLARGINE (RDNA ORIGIN) API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of INSULIN GLARGINE (RDNA ORIGIN) manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A INSULIN GLARGINE (RDNA ORIGIN) supplier is an individual or a company that provides INSULIN GLARGINE (RDNA ORIGIN) active pharmaceutical ingredient (API) or INSULIN GLARGINE (RDNA ORIGIN) finished formulations upon request. The INSULIN GLARGINE (RDNA ORIGIN) suppliers may include INSULIN GLARGINE (RDNA ORIGIN) API manufacturers, exporters, distributors and traders.
click here to find a list of INSULIN GLARGINE (RDNA ORIGIN) suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
A INSULIN GLARGINE (RDNA ORIGIN) DMF (Drug Master File) is a document detailing the whole manufacturing process of INSULIN GLARGINE (RDNA ORIGIN) active pharmaceutical ingredient (API) in detail. Different forms of INSULIN GLARGINE (RDNA ORIGIN) DMFs exist exist since differing nations have different regulations, such as INSULIN GLARGINE (RDNA ORIGIN) USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A INSULIN GLARGINE (RDNA ORIGIN) DMF submitted to regulatory agencies in the US is known as a USDMF. INSULIN GLARGINE (RDNA ORIGIN) USDMF includes data on INSULIN GLARGINE (RDNA ORIGIN)'s chemical properties, information on the facilities and procedures used, and details about packaging and storage. The INSULIN GLARGINE (RDNA ORIGIN) USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of INSULIN GLARGINE (RDNA ORIGIN) suppliers with USDMF on PharmaCompass.
The Pharmaceuticals and Medical Devices Agency (PMDA) established the Japan Drug Master File (JDMF), also known as the Master File (MF), to permit Japanese and foreign manufacturers of drug substances, intermediates, excipients, raw materials, and packaging materials (‘Products’) to voluntarily register confidential information about the production and management of their products in Japan.
The INSULIN GLARGINE (RDNA ORIGIN) Drug Master File in Japan (INSULIN GLARGINE (RDNA ORIGIN) JDMF) empowers INSULIN GLARGINE (RDNA ORIGIN) API manufacturers to present comprehensive information (e.g., production methods, data, etc.) to the review authority, i.e., PMDA (Pharmaceuticals & Medical Devices Agency).
PMDA reviews the INSULIN GLARGINE (RDNA ORIGIN) JDMF during the approval evaluation for pharmaceutical products. At the time of INSULIN GLARGINE (RDNA ORIGIN) JDMF registration, PMDA checks if the format is accurate, if the necessary items have been included (application), and if data has been attached.
click here to find a list of INSULIN GLARGINE (RDNA ORIGIN) suppliers with JDMF on PharmaCompass.
A INSULIN GLARGINE (RDNA ORIGIN) written confirmation (INSULIN GLARGINE (RDNA ORIGIN) WC) is an official document issued by a regulatory agency to a INSULIN GLARGINE (RDNA ORIGIN) manufacturer, verifying that the manufacturing facility of a INSULIN GLARGINE (RDNA ORIGIN) active pharmaceutical ingredient (API) adheres to the Good Manufacturing Practices (GMP) regulations of the importing country. When exporting INSULIN GLARGINE (RDNA ORIGIN) APIs or INSULIN GLARGINE (RDNA ORIGIN) finished pharmaceutical products to another nation, regulatory agencies frequently require a INSULIN GLARGINE (RDNA ORIGIN) WC (written confirmation) as part of the regulatory process.
click here to find a list of INSULIN GLARGINE (RDNA ORIGIN) suppliers with Written Confirmation (WC) on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing INSULIN GLARGINE (RDNA ORIGIN) as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for INSULIN GLARGINE (RDNA ORIGIN) API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture INSULIN GLARGINE (RDNA ORIGIN) as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain INSULIN GLARGINE (RDNA ORIGIN) and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a INSULIN GLARGINE (RDNA ORIGIN) NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of INSULIN GLARGINE (RDNA ORIGIN) suppliers with NDC on PharmaCompass.
INSULIN GLARGINE (RDNA ORIGIN) Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of INSULIN GLARGINE (RDNA ORIGIN) GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right INSULIN GLARGINE (RDNA ORIGIN) GMP manufacturer or INSULIN GLARGINE (RDNA ORIGIN) GMP API supplier for your needs.
A INSULIN GLARGINE (RDNA ORIGIN) CoA (Certificate of Analysis) is a formal document that attests to INSULIN GLARGINE (RDNA ORIGIN)'s compliance with INSULIN GLARGINE (RDNA ORIGIN) specifications and serves as a tool for batch-level quality control.
INSULIN GLARGINE (RDNA ORIGIN) CoA mostly includes findings from lab analyses of a specific batch. For each INSULIN GLARGINE (RDNA ORIGIN) CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
INSULIN GLARGINE (RDNA ORIGIN) may be tested according to a variety of international standards, such as European Pharmacopoeia (INSULIN GLARGINE (RDNA ORIGIN) EP), INSULIN GLARGINE (RDNA ORIGIN) JP (Japanese Pharmacopeia) and the US Pharmacopoeia (INSULIN GLARGINE (RDNA ORIGIN) USP).